Table 2 Important clinical data and technical details of the ⁶⁸Ga-PSMA ligand PET/CT examination

Clinical Notes:

In patients with primary PC the following information should be included:

 – date of diagnosis

 – type of verification of diagnosis (biopsy results, time of biopsy, Gleason score)

 – current PSA value

 – previous imaging results

 – relevant further diagnoses (e.g. renal insufficiency, other malignancies)

In patients with biochemical recurrence additional information is necessary:

 – previous surgery and therapy (e.g. antihormonal treatment, radiation therapy, chemotherapy)

 – initial PSA value, PSA nadir, facultative information on PSA-kinetics

Technical Details:

 – exact name of the radiopharmaceutical agent and applied activity, time of scan start post injection, number of bed positions and time per bed position, body weight

 – Information concerning medication administered as preparation of the PET scan (e.g. furosemide)

 – CT-protocol: low-dose or/and diagnostic CT, contrast agent application (oral/rectal/ intravenous, information on concentrations and volumes, native, arterial, portalvenous), scanned portion of the body